2024 Volume 14 Issue 6 Pages 53-61
Measurement of minimal residual disease (MRD) is a recommended component of multiple myeloma (MM) management; however, its use in routine clinical practice is associated with some challenges. This observational study aimed to understand the use of MRD measurement in clinical settings in Japan. Physicians employed by hematology departments of medium-large hospitals who had treated more than 2 individuals with MM in the previous year were eligible to participate. Data were collected from physicians via an online questionnaire. In total, 85% of respondents reported that they currently utilize MRD measurement, most often to determine treatment response and for future treatment planning. The most commonly used sensitivity threshold to determine MRD was 10–5. Overall, more than 70% of respondents indicated they would conduct MRD measurement in the future, but desired additional clinical evidence regarding the impact of MRD status on treatment response and the correlation between MRD status and prognosis.
